Impact of Inflation Reduction Act on Insulin Prices for Medicare Beneficiaries
Discover how the Inflation Reduction Act impacts insulin prices for Medicare enrollees, enhancing access and affordability in healthcare.
U.S. Prospective MFN Pricing Could Balance Drug Costs and Innovation
Explore how the U.S. prospective most-favored-nation (MFN) pricing strategy aims to lower drug prices while preserving pharmaceutical innovation and encouraging fair global contributions to R&D funding.
Medicare Changes to Orphan Drug Price Negotiation Increase Costs
Recent legislative changes to Medicare’s drug price negotiation program expand orphan drug exclusions, delaying price negotiation for expensive specialty drugs and increasing costs for Medicare beneficiaries.
IQVIA Study Finds High Medicare Part D Denial Rates for New Chronic Condition Medications
IQVIA study reveals Medicare Part D plans frequently deny initial access to medications for chronic conditions, highlighting payer policy and compliance challenges.
U.S. Pushes ‘Most Favored Nation’ Drug Pricing Policy Amid Legal and Industry Challenges
The U.S. administration advances a 'most favored nation' drug pricing policy to align Medicare prices with global low points, aiming to reduce prescription costs amid industry resistance and anticipated legal challenges.